The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Why should CD19 CAR-T be the preferred therapy for Richter’s transformation?
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on why CD19 CAR T-cell therapy should be the preferred treatment approach for patients with Richter’s transformation, highlighting that it provides a therapeutic strategy with fewer adverse events than allogeneic stem cell transplantation (alloSCT) for those patients who have failed on chemoimmunotherapy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
